BiPar Sciences Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
20
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$539M
BiPar Sciences General Information
Description
Developer of tumor-selective drugs designed to target multiple cancer types including therapy-resistant and difficult-to-treat cancers. The company offers a poly ribose polymerase inhibitor for metastatic triple-negative breast cancer, ovarian cancer, and other malignancies, a follow-on inhibitor candidate for pancreatic cancer, and an iodothyronine program with anti-tubulin properties, thereby enabling healthcare providers to enhance the anti-tumor effects of chemotherapy.
Contact Information
Website
www.biparsciences.comCorporate Office
- 400 Oyster Point Boulevard
- Suite 200
- South San Francisco, CA 94080
- United States
Corporate Office
- 400 Oyster Point Boulevard
- Suite 200
- South San Francisco, CA 94080
- United States
BiPar Sciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 15-Apr-2009 | $539M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series C) | 12-Jan-2009 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B1) | 30-Dec-2008 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 26-Feb-2007 | Completed | Generating Revenue | |||
| 2. Debt - General | 14-Jun-2006 | $5M | $18M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 20-Dec-2004 | $13M | $13M | Completed | Startup |
BiPar Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A | 29,893,629 | $0.001000 | $0.03 | $0.44 | $0.44 | 1x | $0.44 | 21.71% |
BiPar Sciences Patents
BiPar Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20120245117-A1 | Methods of treating squamous cell lung cancer with 4-iodo-3-nitrobenzamide in combination with gemcitabine and carboplatin | Inactive | 04-Mar-2011 | ||
| AU-2011282223-A1 | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents | Inactive | 19-Jul-2010 | ||
| CA-2805774-A1 | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents | Inactive | 19-Jul-2010 | ||
| EP-2595618-A1 | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents | Inactive | 19-Jul-2010 | ||
| WO-2012012448-A1 | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents | Inactive | 19-Jul-2010 | A61K31/4745 |
BiPar Sciences Signals
BiPar Sciences Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Asset Management Ventures | Venture Capital | Minority | ||
| Canaan Partners | Venture Capital | Minority | ||
| Cercano Management | PE/Buyout | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| Lighthouse Capital Partners | Venture Capital | Minority |
BiPar Sciences FAQs
-
When was BiPar Sciences founded?
BiPar Sciences was founded in 2002.
-
Where is BiPar Sciences headquartered?
BiPar Sciences is headquartered in South San Francisco, CA.
-
What is the size of BiPar Sciences?
BiPar Sciences has 20 total employees.
-
What industry is BiPar Sciences in?
BiPar Sciences’s primary industry is Drug Discovery.
-
Is BiPar Sciences a private or public company?
BiPar Sciences is a Private company.
-
What is the current valuation of BiPar Sciences?
The current valuation of BiPar Sciences is .
-
What is BiPar Sciences’s current revenue?
The current revenue for BiPar Sciences is .
-
How much funding has BiPar Sciences raised over time?
BiPar Sciences has raised $78M.
-
Who are BiPar Sciences’s investors?
Asset Management Ventures, Canaan Partners, Cercano Management, Domain Associates, and Lighthouse Capital Partners are 5 of 12 investors who have invested in BiPar Sciences.
-
When was BiPar Sciences acquired?
BiPar Sciences was acquired on 15-Apr-2009.
-
Who acquired BiPar Sciences?
BiPar Sciences was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process